Upswitch
Get startedStart as a business owner
Log In
  1. Home
  2. Companies
  3. Pharma Universalis
  4. Financials
Public annual accounts

Pharma Universalis financials

A multi-period view of the public annual-account figures reported for Pharma Universalis, with comparable measures and links to available source documents.

Company overview
Registry number

1004253371

Fiscal coverage

2024–2025

Public sources

cbso_bulk

Data updated

Jul 27, 2026

Financial evidence

Latest movements for Pharma Universalis

2025 versus 2024

Operating line
€59,622

+4%

EBITDA
€59,622

+4.2%

Total assets
€129,198

+81.2%

Equity
€94,403

+94.3%

EBITDA margin +100% · Equity ratio +73.1%

Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.

Public company datasets

Explore the underlying reports

Valuation

2 valuation checkpoints · 2024 to 2025 · Method family

Open report
Upswitch

Knowing your worth is a right, not a privilege.

know it · build it strong · hand it on

Product

  • The Value Curve
  • Your workspace
  • Business Card
  • Pricing
  • Valuation methods
  • Capital gains tax 2026

Solutions

  • For business owners
  • For buyers
  • For Advisors
  • For banks & lenders
  • For private equity

Markets

  • Companies
  • European SME multiples
  • Multiples database

Company

  • Manifesto
  • Blog
  • Security

Legal

  • Privacy
  • Terms
Log in·See what could be weakening my business

Upswitch BV: Zetel: Tuinwijk ter Heide 69, 9050 Gentbrugge, België: Ondernemingsnr.: 1033.441.760-BTW: BE 1033.441.760-RPR Ondernemingsrechtbank Gent - hello@upswitch.app

© 2026 Upswitch

·

Made within Ghent, Belgium

Multi-year filings

Filed annual accounts by fiscal year

Public regulator-filed figures across 2 years.

Source: NBB/CBSO
Fiscal year
Gross margin
EBITDA
Total assets
Equity
Filing
202531 Dec 2025€59,622€59,622€129,198€94,403-
202431 Dec 2024€57,319€57,214€71,306€48,581-
Gross margin line from gross margin (abbreviated schema). This is not reported turnover, so it is not used as a public valuation base.EBITDA basis: operating profit plus full add-backs.